Cheaper Compounded Drug Offers Rare-Disease Hope
Seven Indian children with a rare thyroid-related condition may gain access to a lifelong medicine priced far below the commercial tablet.
Updated on Nov. 5, 2026 in Allergies

Dutch and Indian physicians and civil society groups have arranged for tiratricol, a thyroid-related medicine, to be custom-compounded in The Hague for seven children in India who have Allan Herndon-Dudley Syndrome, a rare condition caused by MCT8 deficiency. The compounded version is priced at 1.8 euro per capsule, far below the commercial tablet price in Germany.
Why it matters
The drug is prescribed for life, and families face unsustainable costs at the commercial price, which can exceed Rs 3 lakh per month for one family importing from Germany. The effort shows how custom compounding and public-interest coordination may offer an alternative route to access for rare-disease patients when commercial pricing is out of reach.
The price comparison rests on pharmacy compounding pricing and commercial list prices for tiratricol, with the cost of one family's monthly imports from Germany as a real-world reference. The underlying efficacy research cited is a 2014 Erasmus MC study backed by 14 million euro in public funding, which found the drug could treat Allan Herndon-Dudley Syndrome.
The players
Egetis
A pharmaceutical company that holds the European marketing authorisation for tiratricol and sells it in Germany.
Erasmus MC
A Dutch academic medical centre whose 2014 research found tiratricol could treat Allan Herndon-Dudley Syndrome.
Pharmaceutical Accountability Foundation
A Dutch organisation coordinating the effort to make tiratricol available to children in India.
Transvaal Pharmacy
A pharmacy in The Hague that will compound tiratricol at 1.8 euro per capsule.
The details
Tiratricol has been sold in France since 1974 for thyroid conditions, and the study found it could address the thyroid hormone signaling problem caused by MCT8 deficiency, which blocks thyroid hormone from reaching the brain. Compounding means a pharmacy custom-makes a medicine in small quantities, which allows the drug to be produced at a fraction of the commercial tablet price. The Pharmaceutical Accountability Foundation started the Dutch-India collaboration after a news report on the funding effort drew its attention. Erasmus MC had sold the intellectual property rights to Egetis without a fair price clause, which is the context for the current pricing.
Timeline
1974: Tiratricol entered the French market for thyroid conditions.
2014: Erasmus MC research found tiratricol could treat AHDS.
2025: Egetis received European marketing authorisation with 10 years of market exclusivity.
November 5, 2026: Compounding arrangement reported for seven children in India.
Health Landscape
Tiratricol illustrates a pattern in which publicly funded research leads to a single commercial owner that can raise prices sharply, as the German price rose from 0.35 euro per tablet in France in 2017 to almost 180 euro by 2026. Compounding and coordinated civil-society efforts are emerging as a way for rare-disease families to reach medicines that remain available in principle but out of reach in practice.
If you or a family member lives with a rare metabolic or thyroid-related condition, the cost of a lifelong medicine can shape treatment access, so it is worth raising affordability and alternative sourcing with your physician or specialist. Families facing high commercial prices may want to ask whether custom compounding or other supply routes are appropriate in their setting.
The takeaway
Publicly funded research can leave patients exposed to steep prices when rights pass to a single commercial owner, and families facing lifelong costs should bring affordability questions to their clinicians. Ask a specialist whether lower-cost compounded or alternative supply options are appropriate for your situation.
Further reading
Readers tracking rare-disease drug access can explore more in the Allergies section.
Source note: This article includes information reported by The Times of India.


